Dry age-related macular degeneration currently has no FDA-approved treatments but the research of Clover Therapeutics has yielded two candidates. The biotech startup has made progress in the past two years under CEO Cheng Zhang and it’s now revealing more details about its approach, a new corporate identity, and a Series A financing that puts it on the path to the clinic.
A Kodiak Sciences drug failed to beat a Regeneron Pharmaceuticals product in a key test in the wet form of age-related macular degeneration. The biotech says the failure is due to a subset of undertreated patients, but the results raise the stakes for the drug, its lead product candidate, in other eye diseases.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Unity Biotechnology's corporate restructuring is a cash-saving move that allows the company to focus resources on its lead program, a drug in Phase 2 testing for diabetic macular edema and wet age-related macular degeneration. Unity previously restructured in 2020 following the Phase 2 failure of its osteoarthritis drug.
Sanofi is committing up to $60 million to Gyroscope Therapeutics, a clinical-stage biotech whose lead program could become the first gene therapy for a particular vision loss disorder. The deal also gives the pharma giant right of first refusal on that gene therapy in certain geographies.
BlueRock Therapeutics, a Bayer subsidiary, is teaming up with Opsis Therapeutics and Fujifilm Cellular Dynamics in an R&D pact focused on developing stem cell therapies for eye diseases. BlueRock is paying its new partners $30 million up front to kick off the alliance.
Atlas Venture, Lightstone Ventures and OrbiMed co-led the Series A for the therapeutics business, which is focused on genetic causes for the condition.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Iconic Therapeutics is using Tissue Factor biology to create new treatment for age-related macular degeneration with retinal disease in addition to cancer.
Vision care, especially for patients with Age-related Macular Degeneration, is being improved drastically with the integration of DigiSight's mobile platform, Paxos. It also provides an abundant source of data for pharmaceutical companies.
It's tough to detect macular degeneration until it's gotten pretty serious. Pennsylvania startup Maculogix has a device that picks up on signs early.